Ibogaine for Parkinson's
Disease. 100 Patients. 62% Improvement

The dashboard below presents aggregated outcome trajectories from all 100 patients across 7 treatment timepoints. from baseline through Day 90, using 8 validated clinical scales spanning the full motor and non-motor symptom spectrum. These instruments include the UPDRS (Unified Parkinson's Disease Rating Scale, the gold standard for Parkinson's motor assessment), Hoehn & Yahr staging, the Berg Balance Scale, and 5 domain-specific scales capturing gait and balance, bradykinesia, rigidity, tremor, and bulbar function. Patients in this cohort represented Hoehn & Yahr stages 1 through 4 at enrollment, spanning the full range of early-to-advanced idiopathic Parkinson's disease.

This multi-scale architecture was deliberately designed to capture ibogaine's therapeutic response across distinct pathophysiological pathways: dopaminergic circuit restoration, cerebellar and brainstem motor circuit remodeling, and the neurotrophic factor upregulation that may address the underlying neurodegeneration. Tracking all 8 scales simultaneously allows the clinical team to identify which symptom domains respond most rapidly, which require longer timelines, and whether disease stage at enrollment predicts treatment response magnitude.

The trajectory data reveals differential response rates across motor domains that carry meaningful mechanistic implications. Gait and balance (85% improvement) and bulbar function, encompassing speech clarity, swallowing efficiency, and sialorrhea control, showed the most dramatic and rapid response (90% improvement), suggesting that ibogaine's neurotrophic factor upregulation preferentially targets the brainstem and cerebellar circuits affected in early-to-moderate Parkinson's disease. These circuits rely heavily on GDNF-responsive dopaminergic and non-dopaminergic pathways that appear particularly sensitive to ibogaine's neuroprotective effects.

Tremor (62% improvement) showed the most modest response among the five motor domains, consistent with tremor-predominant Parkinson's disease's distinct pathophysiology. Tremor circuits in Parkinson's involve thalamic oscillatory networks, specifically the ventral intermediate nucleus. that operate through pathways partially distinct from the nigrostriatal dopaminergic system driving rigidity and bradykinesia. This differential response profile is not a limitation but rather a diagnostic signal: it confirms that ibogaine's mechanism targets dopaminergic and brainstem circuits with greater specificity than the thalamic circuitry underlying tremor, which may benefit from complementary interventions in tremor-predominant presentations.

UPDRS Part III. the Motor Examination, is the universally accepted primary endpoint for Parkinson's therapeutic efficacy trials and the standard by which all interventions, from levodopa to deep brain stimulation, are benchmarked. This 33-item clinician-administered assessment evaluates speech, facial expression, rest tremor across all body segments, action and postural tremor, rigidity at neck and limbs, finger tapping, hand movements, rapid alternating hand movements, leg agility, arising from a chair, posture, gait, postural stability, and global body bradykinesia. The comprehensiveness of UPDRS Part III is what makes it the definitive motor outcome measure. it captures the full clinical expression of Parkinson's motor impairment in a single standardized score.

The following baseline-to-post comparison presents domain-specific scores across the five primary symptom domains tracked in this cohort, demonstrating the magnitude and distribution of motor improvement achieved across 100 patients. Bars represent cohort-average scores in the clinical scale units for each domain, with lower post-treatment values indicating improvement. The scale values are not identical across domains, each reflects its own validated scoring instrument, but the visual comparison makes clear the consistency of response direction across all five domains.

The domain-specific score reductions demonstrate improvement across virtually every assessed motor category, with the directional consistency being as clinically significant as the magnitude. Bulbar function. the highest-responding domain at 90%, translates directly into patient-reported improvements in speech intelligibility and reduced drooling that family members and caregivers notice immediately and that profoundly affect quality of life. Gait and balance improvement at 85% crosses the clinically established threshold for meaningful fall risk reduction, addressing one of the most consequential complications of advancing Parkinson's disease.

The clinical significance extends beyond aggregate domain numbers. Thirty-four percent of patients demonstrated reduced levodopa dose requirements at Day 90. a finding that, if replicated in controlled studies, would suggest genuine disease-modifying rather than purely symptomatic effects. This observation is consistent with ibogaine's proposed GDNF-mediated neuroprotective mechanism, which would predict partial restoration of endogenous dopaminergic capacity rather than simple receptor modulation layered on top of progressive degeneration.